The EMERALD trial investigators randomly assigned 478 patients with ER+, HER2- advanced breast cancer on a 1:1 basis to receive elacestrant or physician’s choice of standard therapy, which was defined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback